Answers are grounded in this paper and cite their sources.
Natural killer (NK) cells are promising candidates for adoptive immunotherapy, but their ex vivo expansion is often accompanied by reduced cellular fitness and functional heterogeneity. Here, we identified that dasatinib, an FDA-approved tyrosine kinase inhibitor, could improve the expansion and antitumor function of NK cells. While dasatinib treatment from the start of culture impaired NK cell expansion, the introduction of dasatinib after the early expansion phase improved NK cell yields and viability without compromising NK cell purity. Transcriptomic analysis showed that dasatinib priming suppressed inflammatory signaling pathways and reduced the expression of apoptosis-related genes. Both transcriptomic and phenotypic analyzes further demonstrated downregulation of inhibitory signaling components, including SHP-1 and killer cell immunoglobulin-like receptor (KIR) family members. In line with these molecular changes, dasatinib-primed NK cells displayed enhanced cytotoxicity against tumor cells expressing high levels of MHC class I, consistent with modulation of MHC class I-related inhibitory signaling. Moreover, dasatinib priming improved the antitumor activity of anti-CD19 CAR-NK cells and enhanced cytotoxicity against MHC class I-expressing CD19+ tumor cells. Collectively, these findings identify dasatinib priming as a simple and clinically applicable strategy to improve the function and antitumor efficacy of expanded NK cells and CAR-NK cells.
No takes yet. Share an insight, caveat, or question.
Jo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: